sur Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences Reveals Promising Preclinical Data for DNase I in Cancer Therapy

Xenetic Biosciences, Inc. presented encouraging preclinical findings at the Society for Immunotherapy of Cancer Spring Meeting in 2025. The study highlights the potential of DNase I to enhance the effectiveness of chimeric antigen receptor (CAR) T cell therapies for cancer treatment. Specifically, DNase I was shown to degrade neutrophil extracellular traps (NETs), allowing for improved T cell infiltration and restored functionality. This combination approach, tested in a B16 melanoma murine model, showed suppressed lung metastasis and extended survival rates compared to CAR T cell monotherapy alone.
The research indicates that DNase I not only boosts the tumor-fighting potential of CAR T cells but also reduces T cell exhaustion markers such as PD-1 and TIM-3. This suggests a mitigation of the immunosuppressive tumor microenvironment effects, thus enhancing the therapeutic efficacy of current treatments.
Xenetic is advancing its DNase-based technology toward Phase 1 clinical trials, aiming to address unmet needs in treating pancreatic carcinoma and other solid tumors. Initial studies combining DNase I with chemotherapy and immunotherapies in colorectal cancer models have been completed, with plans to continue exploring this promising therapeutic strategy.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Xenetic Biosciences, Inc.